BACKGROUND: The Trefoil Factor 1 (TFF1/pS2), a peptide consisting of 60 amino acids, is the most abundant estrogen-induced messenger RNA present in MCF-7 breast cancer cells. The objective of this work was to evaluate the cytosolic TFF1 content in breast carcinomas, its possible relationship with different clinical-pathological parameters, and its potential prognostic significance and predictive value. METHODS: Cytosolic TFF1 levels were examined by immunoradiometric assay in 1031 patients with invasive breast cancer. The median follow-up period was of 50 months. RESULTS: There was a wide variability of cytosolic TFF1 levels in tumors (0.9-743.2 ng/mg protein). Statistical analysis showed that TFF1 levels were significantly higher in premenopausal patients (p = 0.001), as well as in tumors showing any of the following characteristics: good differentiation (p = 0.0001), ER and PgR positivity (p = 0.0001 and p = 0.001, respectively), diploidy (p = 0.045) and a high S-phase fraction (p = 0.001). In addition, the presence of high intratumoral TFF1 levels (cut-off: 2 ng/mg protein) was independently associated with a shorter overall survival in the group of patients as a whole (p = 0.001) as well as in the subgroup with node-negative breast cancer (p = 0.0004). Likewise, high intratumoral TFF1 levels were associated with a more prolonged overall survival in patients who received adjuvant tamoxifen (p = 0.004). CONCLUSIONS: In breast cancer patients, intratumoral TFF1 levels are associated with a better clinical outcome, especially in those with node-negative tumors. In addition, TFF1 levels have a low but significant predictive value in regards to response to adjuvant therapy with tamoxifen.
BACKGROUND: The Trefoil Factor 1 (TFF1/pS2), a peptide consisting of 60 amino acids, is the most abundant estrogen-induced messenger RNA present in MCF-7 breast cancer cells. The objective of this work was to evaluate the cytosolic TFF1 content in breast carcinomas, its possible relationship with different clinical-pathological parameters, and its potential prognostic significance and predictive value. METHODS: Cytosolic TFF1 levels were examined by immunoradiometric assay in 1031 patients with invasive breast cancer. The median follow-up period was of 50 months. RESULTS: There was a wide variability of cytosolic TFF1 levels in tumors (0.9-743.2 ng/mg protein). Statistical analysis showed that TFF1 levels were significantly higher in premenopausal patients (p = 0.001), as well as in tumors showing any of the following characteristics: good differentiation (p = 0.0001), ER and PgR positivity (p = 0.0001 and p = 0.001, respectively), diploidy (p = 0.045) and a high S-phase fraction (p = 0.001). In addition, the presence of high intratumoral TFF1 levels (cut-off: 2 ng/mg protein) was independently associated with a shorter overall survival in the group of patients as a whole (p = 0.001) as well as in the subgroup with node-negative breast cancer (p = 0.0004). Likewise, high intratumoral TFF1 levels were associated with a more prolonged overall survival in patients who received adjuvant tamoxifen (p = 0.004). CONCLUSIONS: In breast cancerpatients, intratumoral TFF1 levels are associated with a better clinical outcome, especially in those with node-negative tumors. In addition, TFF1 levels have a low but significant predictive value in regards to response to adjuvant therapy with tamoxifen.
Authors: Mohammed Soutto; Abbes Belkhiri; M Blanca Piazuelo; Barbara G Schneider; Dunfa Peng; Aixiang Jiang; M Kay Washington; Yasin Kokoye; Sheila E Crowe; Alexander Zaika; Pelayo Correa; Richard M Peek; Wael El-Rifai Journal: J Clin Invest Date: 2011-04-01 Impact factor: 14.808
Authors: Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang Journal: Mol Cell Proteomics Date: 2013-05-23 Impact factor: 5.911
Authors: E Buache; N Etique; F Alpy; I Stoll; M Muckensturm; B Reina-San-Martin; M P Chenard; C Tomasetto; M C Rio Journal: Oncogene Date: 2011-02-28 Impact factor: 9.867
Authors: Milan Markićević; Radan Džodić; Marko Buta; Ksenija Kanjer; Vesna Mandušić; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević Journal: Int J Med Sci Date: 2014-05-01 Impact factor: 3.738
Authors: Maryam Althobiti; Khloud A El-Sharawy; Chitra Joseph; Mohammed Aleskandarany; Michael S Toss; Andrew R Green; Emad A Rakha Journal: Breast Cancer Res Treat Date: 2021-08-28 Impact factor: 4.872